E. Oger, Incidence of venous thromboembolism: A community-based study in western france. Epi-getbp study group. Groupe d'etude de la thrombose de bretagne occidentale, Thromb Haemost, vol.83, pp.657-660, 2000.
URL : https://hal.archives-ouvertes.fr/hal-00726218

T. Alexander and . Cohen, « Venous Thromboembolism (VTE) in Europe. The Number of VTE Events and Associated Morbidity and Mortality, Thrombosis and Haemostasis, vol.98, issue.4, pp.756-764, 2007.

R. Oudega, G. Karel, . Moons, W. Et-arno, and . Hoes, « Ruling Out Deep Venous Thrombosis in Primary Care

«. Christiaens, Idiopathic venous thromboembolic disease. risk factors for recurrence in 2006] », Archives des maladies du coeur et des vaisseaux 100, pp.133-138, 2007.

R. H. White, The Epidemiology of Venous Thromboembolism, Circulation, vol.107, issue.90231, pp.4-8, 2003.
DOI : 10.1161/01.CIR.0000078468.11849.66

«. Blanchemaison and . Epidemiologie, physiopathologie et diagnostic des thromboses veineuses profondes des membres inférieurs, pp.87-90

M. Koopman, Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home, New England Journal of Medicine, vol.334, issue.11, pp.682-687, 1996.
DOI : 10.1056/NEJM199603143341102

. Levine, « A Comparison of Low-molecular-weight Heparin Administered Primarily at Home with

. Belcaro, « Comparison of Low-molecular-weight Heparin, Administered Primarily at Home, with

U. Heparin, Administered in Hospital, and Subcutaneous Heparin, Administered at Home for Deepvein Thrombosis, Angiology, vol.50, issue.10, pp.781-787, 1999.

. Mismetti, « [Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients], 127?136. 11 AFSSAPS. Recommandation de bonne pratique. Prévention et traitement de la maladie thromboembolique veineuse en médecine, 2009.

P. Bertoletti and . Mismetti, Les nouveaux anticoagulants dans la maladie thrombo-embolique veineuse, Revue des Maladies Respiratoires, vol.28, issue.8, pp.1008-1016, 2011.
DOI : 10.1016/j.rmr.2010.12.014

X. Delavenne and «. , Am??liorations pharmacologiques apport??es par les nouveaux anticoagulants oraux, La Presse M??dicale, vol.42, issue.9, pp.1206-1212, 2013.
DOI : 10.1016/j.lpm.2013.06.008

M. Zalesak, Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin, Circulation: Cardiovascular Quality and Outcomes, vol.6, issue.5
DOI : 10.1161/CIRCOUTCOMES.113.000192

G. Agnelli, C. Becattini, and L. Franco, « New Oral Anticoagulants for the Treatment of Venous Thromboembolism », Best Practice & Research, Clinical Haematology, vol.26, issue.2, pp.151-161, 2013.

. Netter, Attlas d'anatomie humaine, pp.526-530, 2011.

R. Berne and M. Levy, Cardiovascular Physiology, Annual Review of Physiology, vol.43, issue.1, 2001.
DOI : 10.1146/annurev.ph.43.030181.002041

D. Pascal, William Harvey découvre le mouvement circulaire du sang, in La Recherche, N° 400 septembre, p.42, 1628.

R. E. Klabunde and . Uhl, Cardiovascular physiology concepts, La pompe veineuse plantaire : Anatomie et hypothèses physiologiques, pp.9-18, 2005.

R. Virchow, . Thrombose, and . Embolie, Gefässen Entzündung und septische Infektion, Gesammelte Abhandlungen zur wissenschaftlichen Medicin, pp.219-732

C. Kearon and «. , Natural History of Venous Thromboembolism, 2003.

V. Kakkar, The Lancet 294, pp.7614-230, 1969.

N. Nicolaides, The origin of deep vein thrombosis: a venographic study, The British Journal of Radiology, vol.44, issue.525, pp.525-653
DOI : 10.1259/0007-1285-44-525-653

«. Sevitt, The mechanisms of canalisation in deep vein thrombosis, The Journal of Pathology, vol.40, issue.2, pp.153-165, 1973.
DOI : 10.1002/path.1711100207

A. Gallus and J. Hirsh, Treatment of venous thromboembolic disease, Semin Thromb Hemost, vol.2, pp.291-331, 1976.

R. Guanella and «. , Syndrome post-thrombotique : la complication négligée de la maladie thromboembolique veineuse », Revue médicale suisse 372, pp.321-325, 2013.

V. Tagalakis, Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort, The American Journal of Medicine, vol.126, issue.9, 2013.
DOI : 10.1016/j.amjmed.2013.02.024

N. Lindblad, . Sternby, and . Bergqvist, Incidence of venous thromboembolism verified by necropsy over 30 years., BMJ, vol.302, issue.6778, pp.6778-709, 1991.
DOI : 10.1136/bmj.302.6778.709

K. Oger, P. Y. Lacut, and . Scarabin, « Thrombose veineuse profonde : épidemiologie, facteurs de risque acquis ». Annales de cardiologie et, pp.124-128, 2002.
DOI : 10.1016/s0003-3928(02)00083-5

M. Cushman, Epidemiology and Risk Factors for Venous Thrombosis, Seminars in Hematology, vol.44, issue.2, pp.62-69, 2007.
DOI : 10.1053/j.seminhematol.2007.02.004

M. Denheijer, T. Koster, and H. Blom, Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis, New England Journal of Medicine, vol.334, issue.12, pp.759-62, 1996.
DOI : 10.1056/NEJM199603213341203

S. Pelet, The Incidence of Thromboembolic Events in Surgically Treated Ankle Fracture, The Journal of Bone and Joint Surgery-American Volume, vol.94, issue.6, pp.502-506
DOI : 10.2106/JBJS.J.01190

N. and J. Pasi, Epidemiology and Pathophysiology of Cancer-associated Thrombosis, British Journal of Cancer, vol.102, issue.1, 2010.

-. Bosson, A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices, Journal of Internal Medicine, vol.91, issue.24, pp.168-176, 2006.
DOI : 10.1007/s11239-004-0208-6

URL : https://hal.archives-ouvertes.fr/hal-00281342

S. Gallus, « Thromboprophylaxis in Non-surgical Patients: Who, When and How?, Haemostasis, vol.28

A. Blanco-molina, Venous thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry, Thrombosis and Haemostasis, vol.97, issue.2, pp.186-190, 2007.
DOI : 10.1160/TH06-11-0650

«. Bounameaux and . Deep, Venous Thrombosis: An Overview, VASA. Supplementum, vol.25, pp.1-28, 1988.

E. Bounameaux and . Zemp, « [The treatment of deep venous thrombosis of the lower limbs], pp.35-1225, 1988.

S. Wells, « A Simple Clinical Model for the Diagnosis of Deep-vein Thrombosis Combined with

S. Wells, Value of assessment of pretest probability of deep-vein thrombosis in clinical management, The Lancet, vol.350, issue.9094, pp.9094-1795, 1997.
DOI : 10.1016/S0140-6736(97)08140-3

S. Philip and . Wells, « Does This Patient Have Deep Vein Thrombosis?, JAMA: The Journal of the American Medical Association, vol.295, issue.2, 2006.

. Bounameaux, « Plasma Measurement of D-dimer as Diagnostic Aid in Suspected Venous Thromboembolism: An Overview, Thrombosis and Haemostasis, vol.71, issue.1, pp.1-6, 1994.

A. Renée and . Douma, « Using an Age-dependent D-dimer Cut-off Value Increases the Number of Older Patients in Whom Deep Vein Thrombosis Can Be Safely Excluded, Haematologica, vol.97, p.10, 2012.

J. Soto, Clinical significance of a negative D-dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry, Journal of Thrombosis and Haemostasis, vol.340, issue.2, pp.407-410, 2011.
DOI : 10.1111/j.1538-7836.2010.04143.x

D. Nisio, Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review, Journal of Thrombosis and Haemostasis, vol.349, issue.2, pp.296-304, 2007.
DOI : 10.1111/j.1538-7836.2007.02328.x

S. Philip and . Wells, « Evaluation of D-dimer in the Diagnosis of Suspected Deep-vein Thrombosis, The New England Journal of Medicine, vol.349, pp.13-1227, 2003.

. Kearon, Noninvasive Diagnosis of Deep Venous Thrombosis, Annals of Internal Medicine, vol.128, issue.8, pp.663-677, 1998.
DOI : 10.7326/0003-4819-128-8-199804150-00011

. Perrier, Non-invasive diagnosis of venous thromboembolism in outpatients, The Lancet, vol.353, issue.9148, pp.190-195, 1999.
DOI : 10.1016/S0140-6736(98)05248-9

P. Brandjes, « Randomised Trial of Effect of Compression Stockings in Patients with Symptomatic Proximal-vein Thrombosis, Lancet, vol.34915, pp.9054-759, 1997.

P. Prandoni, Below-Knee Elastic Compression Stockings To Prevent the Post-Thrombotic Syndrome, Annals of Internal Medicine, vol.141, issue.4, pp.249-256, 2004.
DOI : 10.7326/0003-4819-141-4-200408170-00004

. Hirsh, « Heparin and Low-molecular-weight Heparin: Mechanisms of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety, pp.489-510, 1998.

J. Ansell, « The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, pp.204-233, 2004.

N. Savina and . Couturaud, Dur??e optimale du traitement anticoagulant au d??cours d???une maladie veineuse thrombo-embolique, Journal des Maladies Vasculaires, vol.36, issue.1, pp.28-32, 2011.
DOI : 10.1016/S0398-0499(11)70005-1

«. Bounameaux, The Novel Anticoagulants: Entering a New Era », Swiss Medical Weekly 139, pp.5-6

P. Bertoletti and . Mismetti, Les nouveaux anticoagulants dans la maladie thrombo-embolique veineuse, Revue des Maladies Respiratoires, vol.28, issue.8, pp.1008-1016, 2011.
DOI : 10.1016/j.rmr.2010.12.014

K. P. Cabral, Pharmacology of the new target-specific oral anticoagulants, Journal of Thrombosis and Thrombolysis, vol.160, issue.5, pp.133-140, 2013.
DOI : 10.1007/s11239-013-0929-5

S. Blech, « The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans », Drug Metabolism and Disposition: The Biological Fate of Chemicals 36, pp.386-399, 2008.

C. Lang, . Freudenberger, and . Weinz, « In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans », Drug Metabolism and Disposition: The Biological Fate of Chemicals 37, pp.1046-1055, 2009.

N. Raghavan, « Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans », Drug Metabolism and Disposition: The Biological Fate of Chemicals 37, pp.74-81, 2009.

M. Michel and S. , « In Vitro Study of the Anticoagulant Effects of Edoxaban and Its Effect on Thrombin Generation in Comparison to Fondaparinux, Thrombosis Research, vol.129, issue.4, pp.77-82, 2012.

J. Stangier, Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment, The Journal of Clinical Pharmacology, vol.11, issue.6, pp.12-1411, 2008.
DOI : 10.1177/0091270008324179

F. Schiele, A specific antidote for dabigatran: functional and structural characterization, Blood, vol.121, issue.18, pp.3554-3562, 2013.
DOI : 10.1182/blood-2012-11-468207

G. Lu, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4, pp.446-451, 2013.
DOI : 10.1038/nm.3102

S. Schulman, « Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism, The New England Journal of Medicine, vol.361, pp.24-2342, 2009.

G. Agnelli, Oral Apixaban for the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.369, issue.9, pp.799-808, 2013.
DOI : 10.1056/NEJMoa1302507

URL : https://hal.archives-ouvertes.fr/hal-00932477

H. Investigators, Edoxaban Versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, The New England Journal of Medicine, vol.369, pp.15-1406, 2013.

G. Debris, Evaluation du niveau de risque cardiovasculaire des médecins généraliste de la région PACA

P. Frappé and S. Liébart, « [New oral anticoagulants in primary care: The general practitioner's point of view], Presse médicale, pp.1267-1273, 1983.

P. Pinaud, Etudes de la prescription de nouveaux anticoagulants oraux dans l'acfa chez les médecins généralistes picard, Thèse de médecine faculté d'Amiens, 2013.

L. Canard and E. , La Sécu victime d'un hold-up de 400 millions d'euros, 2013.

L. Monde, Les mirages des nouveaux anticoagulants. Florence Rosier, 2013.

J. Souilem, J. Cambou, and . Cambus, Coumadine?? vs Pr??viscan????: comparaison du temps pass?? dans la fourchette th??rapeutique de l???INR chez un groupe de patients suivis ?? la clinique des anticoagulants de Toulouse, Journal des Maladies Vasculaires, vol.34, p.28, 2009.
DOI : 10.1016/j.jmv.2009.07.036

. Les, dabigatran (Pradaxa°), rivaroxaban (Xarelto°) : une place très restreinte en pratique, peu d'expérience clinique et pas d'antidote », Prescrire Décembre, 2013.

. Saignement-sous-dabigatran, Pas d'antidote et peu d'expérience clinique», Prescrire, vol.33, issue.353, pp.202-206, 2013.